glp 1 approved for cardiovascular disease Glucagon-like peptide receptor agonists: benefits and mechanisms of action SELECT: Glucagon-like peptide-1 receptor agonist

and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal

GLP-1 receptor agonists are known to suppress appetite, which can lead to a reduced intake of essential micronutrients

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.

Sensitivity analyses showed that the probability of using GLP-1RAs versus insulin being cost-effective for preventing one case of all-cause mortality or hospitalized hypoglycemia ranged from 60 to 100%